# US 9,872,834 B2 · Nanocarrier therapy for treating invasive tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,872,834 B2
- Document ID: US9872834B2
- Status: Granted
- Kind: B2
- Application number: 14/980,578
- Filed: 2015-12-28
- Published: 2016-04-28
- Granted: 2018-01-23
- Earliest claimed: 2009-04-22
- Assignees: Emory University; Georgia Tech Research Corporation; Children's Healthcare of Atlanta, Inc.
- Applicants: Emory University; Georgia Tech Research Corporation; Children's Healthcare of Atlanta, Inc.
- Inventors: Jennifer M. Munson; Ravi V. Bellamkonda; Jack L. Arbiser
- Web page: https://patentgrep.com/patent/US9872834B2

## CPC

- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Liposomes of a size of less than 200 nanometers target tumors and preferentially deliver imipramine blue to tumors, including brain tumors such as gliomas. The imipramine blue decreases the invasiveness of the tumors, and inhibits tumor metastasis. The liposomes include cholesterol and chemically pure phospholipids that are essentially neutral and contain saturated fatty acids of between 16 and 18 carbon atoms, such as distearoylphosphatidyl choline, and can also include one or more pegylated phospholipids, such as DSPE-PEG.

## Claims

### Claim 1

A composition for treating tumors in a patient, comprising unilamellar liposomes containing a therapeutic amount of imipramine blue, or a pharmaceutically-acceptable salt thereof, in a pharmaceutically-acceptable carrier for intraveneous administration,
wherein the liposomes comprise chemically pure phospholipids that are essentially neutral and contain saturated fatty acids of between 16 and 18 carbon atoms.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the liposomes have a size of from about 50 to about 160 nanometers.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the phospholipids are synthetic phospholipids.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the phospholipids comprise distearoylphosphatidyl choline.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the phospholipids comprise a pegylated phospholipid.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the phospholipids comprise DSPC, DSPE-PEG, and cholesterol.

### Claim 7 (depends on 6)

The composition of claim 6, wherein the ratio of DSPC/DSPE-PEG/cholesterol is about 85%/about 5%/about 10%.

### Claim 8 (depends on 1)

The composition of claim 1, further comprising an anti-tumor agent other than imipramine blue.